CJ Bioscience
Korea - SeoulBiotechnology
Focus: CJ Bioscience is a newly founded (2024) Korean biotech company specializing in microbial database, sequencing, and identification services with an early-stage oncology pipeline. The company operates at pre-revenue scale with minimal public visibility.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About CJ Bioscience
AI assessmentNot HiringNo open roles listed right now. Follow CJ Bioscience to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CJRB-101
NSCLCClinical Trials (1)
NCT05877430Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Phase 1/2Help build intelligence for CJ Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.